Cell Therapy in Hematological Malignancies
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 31 May 2025 | Viewed by 1093
Special Issue Editors
Interests: lymphoma; hematological disease; stem cell transplantation; immunotherapy
Special Issues, Collections and Topics in MDPI journals
Interests: experimental medicine; oncology; molecular and clinical pathology; predictive medicine; clinical molecular biology
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Traditionally, the treatment of hematological malignancies mainly included chemotherapy, radiotherapy, and hematopoietic stem cell transplantation (HSCT). However, with advances in tumor immunology, immune targeted therapy, such as monoclonal antibodies, bispecific antibodies, antibody–drug conjugates, and chimeric antigen receptor T (CAR-T) cell therapy, has opened a new avenue for the treatment of malignancies.
Thus, the aim of this Special Issue is to present analyses of biological approaches in the treatment of lymphomas, with particular emphasis on immunological implications.
In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following:
- Immunotherapies, adjuvants and immunomodulators;
- Cell therapy developments and mechanisms of action;
- Immunology mechanisms;
- Immune response to immunotherapies.
We look forward to receiving your contributions.
Dr. Francesco Gaudio
Dr. Stefano Martinotti
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cell therapy
- immunotherapy
- target therapy
- hematological malignancies
- tumor immunology
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
